Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
about
Epidemiology of lung cancerMolecular biology of lung cancerTreatment of advanced squamous cell carcinoma of the lung: a reviewThe Evolution of Therapies in Non-Small Cell Lung CancerMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularTargeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicinePersonalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistanceTargeted therapies in development for non-small cell lung cancerMolecular pathology of non-small cell lung cancer: a practical guide.Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapiesThe impact of the Cancer Genome Atlas on lung cancer.Comprehensive genomic characterization of squamous cell lung cancers.AKT1E¹⁷K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancernab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.Beyond histology: translating tumor genotypes into clinically effective targeted therapies.PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases.Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data.Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expressionCombining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.Diagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients.Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularPerformance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort studyMicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel.Small-cell lung cancers in patients who never smoked cigarettes.Novel agents in development for advanced non-small cell lung cancer.Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare SystemMetastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study.FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma.PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients.Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancerThe challenge of using biomarkers and molecularly targeted drugs to improve cure rate in early stage non-small cell lung cancerMolecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER studyDiagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classificationReevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysisActivation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations.
P2860
Q24600475-46695B5A-E90E-4CAF-A066-5979279422EEQ24606677-950BC0E0-6075-400D-8412-9F19E80FB968Q26775392-8C136E7D-E1FB-408A-98A3-936F244EB6B2Q26786932-3322E3A7-E0EE-461C-BA33-61ADD3AE247BQ26828860-F51423B3-9104-4574-9117-2A129BAD6558Q26865436-FD32458E-0880-4F67-8826-64845549EE8BQ26866517-18E620A7-4F68-451C-8E2A-6D7AE239BA76Q27022852-ACE0CEAE-7696-466F-9F9F-3834D0B52BDCQ27690919-EF83EF89-F2AB-450B-A904-4DA8C85AC5CAQ28083840-036AB5E1-B7CF-459D-8BC2-E94FE5F7AC99Q28084190-AFF2FF89-3406-4F8D-A2F3-20403AEE4761Q28274701-54C667CF-E43B-4EC1-B8EE-BDC7018BFA01Q28550038-C25E6352-343F-404C-BF26-2D9D09250B3FQ33412928-530E0C27-4BBE-49A7-82D9-E7E0FF80A26CQ33560928-CB2FE4C6-1140-4E23-8F83-F11D0077D32AQ33618754-A2879530-334B-40CF-B2AB-716192FCC802Q33648747-B4DE316F-C031-44F0-8ED5-7554EAD0F4A9Q33828083-7DCF2A4E-54FF-4F6A-823B-DF6C64A458C7Q33947862-9CEA5982-E751-49EC-93AF-9A8734EB4864Q33956097-FB075BA3-2B5D-4F83-B681-962FBA5111C3Q34066159-3979FDCF-F459-4A7D-849D-2A1DA4508758Q34109055-D5BA50BF-F8F1-45E9-A592-101B3FA07507Q34150095-7920F5CA-A076-4B70-A46A-F38B540F8EDFQ34159011-CA798EA0-05A1-4F8E-968C-C73820B9E5D2Q34235130-74822CA2-946D-44F6-8201-C07C61C30989Q34293127-3727CEE4-739A-4EC3-884A-B36BA43F3594Q34352284-535BC1A1-833D-4A60-B3B9-A64F7AB362C1Q34389263-253A4F19-7D0E-4D51-A1A0-1673A7C41474Q34608597-E918CC11-8252-43F4-847E-DECD2ABC160DQ34663877-0EA5A0BD-18DA-45D2-A400-787078CBA505Q34860000-0DE4A99C-556F-4DC3-849A-6060643FDF45Q35073348-609C21DC-97D6-40A6-8D6A-331A3A6292CEQ35176080-28F0D079-B7E9-46E2-A8EB-BDECFE2F80DAQ35204324-EBFAD1A1-1FE0-4C66-84B1-69D93EC9DDA7Q35238397-F10FD80F-AEFB-4F0A-8AD9-E84C499DE1CBQ35290441-ACB4F24B-F3EF-403E-A053-A3CE262A858DQ35849985-01507681-FC8F-44F0-8DBF-D7D200B4E0F5Q35875227-474B6243-D008-49A6-8F3E-92BC77B1986BQ35957585-5B11DDC0-5050-4D55-8B6C-47FE13475C08Q35961430-83F2B932-5F4E-479F-BB01-16026FBEBB1A
P2860
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Clarifying the spectrum of dri ...... ence of PIK3CA/AKT1 mutations.
@ast
Clarifying the spectrum of dri ...... ence of PIK3CA/AKT1 mutations.
@en
type
label
Clarifying the spectrum of dri ...... ence of PIK3CA/AKT1 mutations.
@ast
Clarifying the spectrum of dri ...... ence of PIK3CA/AKT1 mutations.
@en
prefLabel
Clarifying the spectrum of dri ...... ence of PIK3CA/AKT1 mutations.
@ast
Clarifying the spectrum of dri ...... ence of PIK3CA/AKT1 mutations.
@en
P2093
P2860
P1476
Clarifying the spectrum of dri ...... ence of PIK3CA/AKT1 mutations.
@en
P2093
Andre L Moreira
Geoffrey R Oxnard
Laura J Tafe
Maria E Arcila
Mark G Kris
Maureen F Zakowski
Natasha Rekhtman
Paul K Paik
William D Travis
P2860
P304
P356
10.1158/1078-0432.CCR-11-2109
P407
P50
P577
2012-01-06T00:00:00Z